For Thursday, January 26th
ATTD, NHYT, ENMD, GENE, ILMN, NWMT
Our Stocks to Watch tomorrow include Attitude Drinks Inc. (OTCBB: ATTD), Neohydro Technologies Corp. (OTCBB: NHYT), EntreMed Inc. (NASDAQ: ENMD), Genetic Technologies Ltd. (NASDAQ: GENE), Illumina Inc. (NASDAQ: ILMN) and NewMarket Technology Inc. (OTC: NWMT).
ATTITUDE DRINKS INCORPORATED (OTCBB: ATTD)
"Up 91.67% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/ATTD.php
Attitude Drinks Inc. is an innovative, beverage brand development company with a focus on functional milk, ready-to-drink beverages. Phase III® Recovery Drink is the company's first, functional milk drink exploiting recent scientific evidence of the benefits of milk and protein as an exercise recovery aid. The February 2010 launch of Phase III marks the first time a sports drink has been formulated from real milk.
ATTD News:
January 24 - Attitude Drinks Announces Authorization in Walgreens Stores Within State of Florida
Attitude Drinks (OTCBB: ATTD), an innovative brand beverage development company and creator of the Phase III® Recovery brand, today announced a sales agreement with Walgreens, of Deerfield, IL.
The brand will be distributed to Walgreens stores throughout the majority of the state. This represents over 800 stores within the chain. Walgreens, a company built around the concept of one stop shopping, has now increased their focus into the health & wellness arena. They are striving to become the first choice for "health & daily living" in promoting what they refer to as a "well experience."
Roy Warren, CEO of Attitude Drinks commented, "The introduction of Phase III® into the authorized Walgreens locations throughout the state of Florida is a great indicator of brand growth and reception within the beverage community. The selling of Phase III® into these Walgreens stores, a chain recognized as one of the strongest drug and convenience stores in the country, is exciting and flattering. We intend to support this fantastic new relationship in raising the sales to their fullest potential."
"We are excited about the authorization of Phase III® Recovery in the Florida Division of Walgreens. It is clear that Florida consumers are looking to purchase Phase III® and now that it is available in Walgreens--problem solved," commented Jack Shea, Executive Vice President of Sales for Attitude.
NEOHYDRO TECHNOLOGIES CORPORATION (OTCBB: NHYT)
"Up 100.00% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/NHYT.php
Neohydro Technologies Corp. engages in the acquisition and exploration of mineral resources. It intends to explore for gold. It owns interest in the Rio Lode Claim, which is located within the Yellow Pine Mining District of Clark County, Nevada. The company, formerly known as Rioridge Resources Corp., was founded in 2007 and is based in Piscataway, New Jersey.
NHYT News:
November 19 - Neohydro Technologies Corp. Releases Income Statement
Neohydro Technologies Corp. (OTCBB: NHYT), a Company focused on “Green” technologies in the automotive, transportation, and power generation sectors, has released its latest income statement. Visit http://yhoo.it/gPbyXJ to view it.
ENTREMED INCORPORATED (NASDAQ: ENMD)
"Up 32.39% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/ENMD.php
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.
ENMD News:
January 23 - EntreMed Secures $10 Million Strategic Financing
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, reported financial results for the three and nine-month periods ending September 30, 2011 .
EntreMed reported a net loss for the third quarter of 2011 of ( $1.3 million ), or ($0.13) per share. This compares with a net loss of ( $2.1 million ), or ($0.24) per share, for the same period last year. For the first nine months of 2011 the reported net loss was ($5.6 million ), or ($0.54) per share as compared to ( $9.2 million ), or ($1.09) per share for 2010.
As of September 30, 2011 , EntreMed had cash and cash equivalents of approximately $2.0 million .
Sara B. Capitelli , EntreMed's Vice President, Finance & Principal Accounting Officer, commented on the third quarter results, "Our financial results for the third quarter are in line with our expectations. Our research and development expenses for the third quarter decreased compared to the previous year as we completed enrollment of patients in the ENMD-2076 Phase 2 ovarian cancer study in 2011. We anticipate fourth quarter operating expenses to continue to decrease. In addition, we expect that the majority of our 2011 revenue will be from royalties on the sales of Thalomid®."
Michael M. Tarnow , EntreMed's Executive Chairman, further commented, "We are thankful to our shareholders for their support of EntreMed. We are moving forward with the planning process for the next clinical trial of ENMD-2076. The initiation of the next trial will necessitate additional resources, and we are continuing to pursue partnering and funding opportunities."
ABOUT ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.
GENETIC TECHNOLOGIES LIMITED (NASDAQ: GENE)
"Up 30.31% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/GENE.php
Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species. Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia.
GENE News:
December 16 - Genetic Technologies Appoints Dr. Mel Bridges as Chairman
The Board of Directors of Genetic Technologies Limited (NASDAQ: GENE) has appointed Dr. Mel Bridges as Chairman and non-executive Director of the Company.
Mel Bridges has over 30 years' experience in the diagnostic and healthcare industries. During this period, Mel has founded and managed successful diagnostics, therapeutics and medical device businesses, co-founding ASX listed Panbio Limited and ImpediMed Limited. During the past three years, Mel has also served a number of prominent roles as director and chairman of public healthcare companies, including chairman of Alchemia Limited, director of ImpediMed Limited, and director of Campbell Brothers and Benitec Limited. Mel also has deep experience with healthcare/biotechnology companies, having served multiple board posts such as chairman of Peptech Limited and non-executive director of Domantis plc.
"Genetic Technologies has been one of the most compelling turnaround stories on the ASX and NASDAQ this year, and looks especially poised for growth as we head into 2012," said Dr. Bridges. "The Company's progress to commercialisation and recent US expansion is a credit to the existing Board and management. I am excited to utilise my experience in the sector to build on this trajectory."
It is with regret that Genetic Technologies accepts the resignation from the Board of Mr. Sid Hack. Sid has made the personal decision to retire, having served as a Director of the Company since November 2008 and as Chairman since November 2009. During this time, he has overseen and guided the Company through a process of re-structuring and focusing the strategy to a sustainable growth path. This process has created shareholder value and laid a solid foundation for future growth. The Board and management of Genetic Technologies would like to take this opportunity to sincerely thank Sid for his stewardship and substantial devotion of time and effort over the past three years.
The Company's outgoing Chairman, Mr. Hack, said, "I am delighted that Mel has agreed to join the Board. His substantial and direct experience in the commercialisation of diagnostics products globally will add tremendous value to the Company. In particular, his knowledge of the breast cancer diagnostics market in North America will help to accelerate the Company's cancer diagnostics business in the USA. I have enjoyed working with my fellow Directors and management to grow and advance Genetic Technologies strategic moves internationally and I wish the Company every success in the future."
An ASX Appendix 3X in respect of Dr. Bridges and an ASX Appendix 3Z in respect of Mr. Hack are each attached to this announcement.
ABOUT BREVAGEN™
The BREVAGen™ breast cancer risk stratification test is a novel genetic test panel that examines a patient's DNA to detect the absence or presence of certain common genetic variations (SNPs) associated with an increased risk for developing breast cancer. The test is designed to help physicians assess aggregate breast cancer risk from these genetic markers, plus factors from a standard clinical assessment based on a patient's family and personal history, thus giving a clearer picture of an individual woman's risk of developing breast cancer. The BREVAGen™ test may be especially useful for women at intermediate risk of developing breast cancer, including those who have undergone breast biopsies, as the test will provide information that can help physicians recommend alternative courses of action, such as more vigilant, targeted surveillance or preventive therapy, on a personalized patient-by-patient basis.
ILLUMINA INCORPORATED (NASDAQ: ILMN)
"Up 46.34% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/ILMN.php
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
ILMN News:
January 25 - Illumina Board of Directors to Review Unsolicited Acquisition Proposal from Roche
Illumina Board of Directors to Review Unsolicited Acquisition Proposal from Roche
Illumina, Inc. (NASDAQ: ILMN), a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, tonight acknowledged the announcement by Roche (OTC: RHHBY) that Roche has made an unsolicited acquisition proposal and intends to commence a tender offer to acquire all of the outstanding shares of Illumina’s common stock for $44.50 per share in cash.
Consistent with its fiduciary duties and responsibilities, and in consultation with its financial and legal advisors, Illumina’s Board of Directors will thoroughly review Roche’s proposal and make a recommendation to stockholders in due course that the Board believes is in the best interests of Illumina stockholders. Illumina stockholders are advised to take no action at this time pending the Board’s recommendation.
Goldman, Sachs & Co. and Bank of America Merrill Lynch are acting as financial advisors and Dewey & LeBoeuf LLP is acting as legal counsel to Illumina.
NEWMARKET TECHNOLOGY INCORPORATED (OTC: NWMT)
"Up 100.00% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/NWMT.php
NewMarket's current portfolio of operating subsidiaries provides systems integration and technology infrastructure services. NewMarket's operations strategically focus on providing technology and support services in emerging and developing economies with high growth rate potential. NewMarket has operating subsidiaries today in China, Singapore, Brazil and Northern Latin America.
NWMT News:
October 27 - China Crescent Enterprises, Inc. Anticipates Potential Business Strategy Updates in Light of Recent NewMarket Technology, Inc. Announcement
China Crescent Enterprises, Inc. ("China Crescent" or the "Company") (OTC: CCTR) announced that it anticipates potential business strategy updates in light of a recent NewMarket Technology, Inc. ("NewMarket") (OTC: NWMT) announcement on October 20, 2011. China Crescent is a majority-owned subsidiary of NewMarket.
On October 20, NewMarket announced that it is exploring new potential investment relationships and an associated change of control event. China Crescent anticipates that any such investment relationship or change of control event of NewMarket would also impact the Company and its business strategy. The entire announcement is available on NewMarket's website.
On October 21, 2011, NewMarket also released a Current Report on Form 8-K to report that it received shareholder approval for an amendment to NewMarket's Articles of Incorporation to increase the number of its authorized shares of common stock. The amendment is solely for the purpose of increasing the number of authorized shares of common stock for NewMarket and specifically does not include a reverse split of its issued and outstanding shares. The 8-K can be reviewed in its entirety at:
China Crescent has no plans at this time to either increase the number of its authorized shares of common stock or reverse split its issued and outstanding shares.
|
